Sangamo Therapeutics Archives -

Pfizer and Sangamo have restarted recruitment of patients into their registration trial for haemophilia A gene therapy giroctocogene

Pfizer, Sangamo resume haemophilia gene therapy trial

https://pharmaphorum.com/news/pfizer-sangamo-resume-haemophilia-gene-therapy-trial/

Catalyst Biosciences is a step closer to challenging Novo Nordisk’s NovoSeven in the haemophilia A and B market

Catalyst’s rival to NovoSeven hits the mark in phase 2 haemophilia trial

https://pharmaphorum.com/news/catalysts-rival-to-novoseven-hits-the-mark-in-phase-2-haemophilia-trial/

Shares in two US gene therapy biotechs have fallen after two cutting-edge treatments failed to produce convincing results

Gene therapy biotech shares sink on inconclusive trial results

https://pharmaphorum.com/news/gene-therapy-biotech-shares-sink-on-inconclusive-trial-results/

Doctors in California have made history by attempting to edit genes within a patient for the first time,

Sangamo edits living patient’s DNA for first time

https://pharmaphorum.com/news/us-doctors-gene-editing/

Sangamo Therapeutics